Rifabutin for treating pulmonary tuberculosis.

Area of Science:

• Pulmonary Medicine
• Infectious Diseases
• Pharmacology

Background:

• Rifamycins are crucial for tuberculosis treatment.
• Rifabutin offers potential advantages over rifampicin, including fewer drug interactions, particularly for HIV-positive patients on antiretrovirals.

Purpose of the Study:

• To compare combination drug regimens containing rifabutin with those containing rifampicin for treating pulmonary tuberculosis.

Main Methods:

• Searched multiple databases (Cochrane, MEDLINE, EMBASE, LILACS) and other sources up to January 2007.
• Included randomized and quasi-randomized trials comparing rifabutin- with rifampicin-containing regimens for tuberculosis.
• Analyzed data using relative risks (RR) with 95% confidence intervals (CI) and performed subgroup analyses by rifabutin dose.

Main Results:

• Five trials (924 participants) met criteria; only one was methodologically adequate.
• No significant difference in cure or relapse rates between rifabutin and rifampicin regimens.
• Adverse events were not significantly different overall, but showed a trend towards increase with higher rifabutin doses, complicated by lack of weight-based dose adjustment.

Conclusions:

• Current evidence does not support substituting rifampicin with rifabutin for first-line tuberculosis treatment.
• HIV-positive individuals, a key potential beneficiary group, are under-represented in existing trials.
• Further research in HIV-positive populations is warranted to evaluate rifabutin's efficacy and safety.